Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014.e1.

Article  CAS  PubMed  Google Scholar 

Crane H, Gofton C, Sharma A, George J. MAFLD: an optimal framework for understanding liver cancer phenotypes. J Gastroenterol. 2023;58:947–64.

Article  PubMed  PubMed Central  Google Scholar 

Venkatesan K, Haroon NN. Management of metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am. 2023;52:547–57.

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–9.

Article  PubMed  Google Scholar 

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

Article  PubMed  Google Scholar 

Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis. Hepatology. 2019;70:1119–33.

Article  PubMed  Google Scholar 

Fouda S, Pappachan JM. Metabolic-associated fatty liver disease: a disastrous human health challenge. Endocrinol Metab Clin North Am. 2023;52:xv–xvi.

Article  PubMed  Google Scholar 

Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169:Itc65–itc80.

Article  PubMed  Google Scholar 

Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res. 2021;52:25–37.

Article  CAS  PubMed  Google Scholar 

Fouda S, Jeeyavudeen MS, Pappachan JM, Jayanthi V. Pathobiology of metabolic-associated fatty liver disease. Endocrinol Metab Clin North Am. 2023;52:405–16.

Article  PubMed  Google Scholar 

Kapoor N, Kalra S. Metabolic-associated fatty liver disease and diabetes: a double whammy. Endocrinol Metab Clin North Am. 2023;52:469–84.

Article  PubMed  Google Scholar 

Marschner RA, Arenhardt F, Ribeiro RT, Wajner SM. Influence of altered thyroid hormone mechanisms in the progression of metabolic dysfunction associated with fatty liver disease (MAFLD): a systematic review. Metabolites. 2022;12:675.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, et al. Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Liver Int. 2021;41:1713–33.

Article  PubMed  Google Scholar 

Lefebvre P, Staels B. Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease. Nat Rev Endocrinol. 2021;17:662–70.

Article  PubMed  Google Scholar 

Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology. 2019;70:1457–69.

Article  CAS  PubMed  Google Scholar 

Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5:673–81.

Article  CAS  PubMed  Google Scholar 

Yang LJ, Zhou JZ, Zheng YF, Hu X, He ZY, Du LJ, et al. Association of non-alcoholic fatty liver disease with total testosterone in non-overweight/obese men with type 2 diabetes mellitus. J Endocrinol Invest. 2023;46:1565–72.

Article  CAS  PubMed  Google Scholar 

Apostolov R, Wong D, Low E, Vaz K, Spurio J, Worland T, et al. Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes. Scand J Gastroenterol. 2023:1–7.

Sarkar M, Yates K, Suzuki A, Lavine J, Gill R, Ziegler T, et al. Low testosterone is associated with nonalcoholic steatohepatitis and fibrosis severity in men. Clin Gastroenterol Hepatol. 2021;19:400–2.e2.

Article  CAS  PubMed  Google Scholar 

De Herdt C, De Block C, Francque S, Verrijken A, Van Dessel K, Van Gaal L, et al. A cross-sectional analysis of the association between testosterone and biopsy-proven non-alcoholic fatty liver disease in men with obesity. Endocrine. 2023;80:54–63.

Article  PubMed  Google Scholar 

Dayton KA, Bril F, Barb D, Lai J, Kalavalapalli S, Cusi K. Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes. PLoS ONE. 2021;16:e0251449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo MQ, Huang ZC, Yang ZH, Liao YH, Xia N, Pan L. Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis. Ther Adv Endocrinol Metab. 2022;13:20420188221106879.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hua X, Zhang H, Yang W, Liu G, Zhang S, Wang Y. SFI, a sex hormone binding globulin based nomogram for predicting non-alcoholic fatty liver disease in the Chinese population. Front Endocrinol. 2023;14:1176019.

Article  Google Scholar 

Oduwole OO, Huhtaniemi IT, Misrahi M. The roles of luteinizing hormone, follicle-stimulating hormone and testosterone in spermatogenesis and folliculogenesis revisited. Int J Mol Sci. 2021;22:12735.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cao W, Xu Y, Shen Y, Wang Y, Ma X, Bao Y. Associations between sex hormones and metabolic-associated fatty liver disease in a middle-aged and elderly community. Endocr J. 2022;69:1007–14.

Article  CAS  PubMed  Google Scholar 

Zhang X, Mou Y, Aribas E, Amiri M, Nano J, Bramer WM, et al. Associations of sex steroids and sex hormone-binding globulin with non-alcoholic fatty liver disease: a population-based study and meta-analysis. Genes. 2022;13:966.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jung ES, Choi EK, Park BH, Chae SW. Serum follicle-stimulating hormone levels are associated with cardiometabolic risk factors in post-menopausal Korean women. J Clin Med. 2020;9:1161.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bertone-Johnson ER, Virtanen JK, Niskanen L, Nurmi T, Ronkainen K, Voutilainen S, et al. Association of follicle-stimulating hormone levels and risk of type 2 diabetes in older postmenopausal women. Menopause. 2017;24:796–802.

Article  PubMed  Google Scholar 

Wang N, Li Q, Han B, Chen Y, Zhu C, Chen Y, et al. Follicle-stimulating hormone is associated with non-alcoholic fatty liver disease in Chinese women over 55 years old. J Gastroenterol Hepatol. 2016;31:1196–202.

Article  CAS  PubMed  Google Scholar 

Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology. 2012;79:194–201.

Article  PubMed  Google Scholar 

Qin X, Lin L, Mo Z, Lv H, Gao Y, Tan A, et al. Reference intervals for serum alpha-fetoprotein and carcinoembryonic antigen in Chinese Han ethnic males from the Fangchenggang Area Male Health and Examination Survey. Int J Biol Markers. 2011;26:65–71.

Article  CAS  PubMed  Google Scholar 

Qin X, Lv H, Mo Z, Chen Z, Lin L, Peng T, et al. Reference intervals for serum sex hormones in Han Chinese adult men from the Fangchenggang Area Male Health and Examination Survey. Clin Lab. 2012;58:281–90.

PubMed  Google Scholar 

Cai J, Lin C, Lai S, Liu Y, Liang M, Qin Y, et al. Waist-to-height ratio, an optimal anthropometric indicator for metabolic dysfunction associated fatty liver disease in the Western Chinese male population. Lipids Health Dis. 2021;20:145.

Artic